AIDS-associated toxoplasma encephalitis
Conditions
Interventions
Group A:TMP-SMX (oral dose of 1.44g, every 8 hours) plus azithromycin (intravenous dose of 0.5g, once a day), for at least 6 weeks
Group B:Synergistic sulfonamides (oral dose of 1.44g, every 8 hours) plus clindamycin (intravenous dose of 0.6 g, every 6 hours), for at least 6 weeks.
Sponsors
Chongqing Public Health Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients will be included in our study if they meet the following criteria: (1) Aged 18 years or older; (2) Confirmed diagnosis of AIDS-associated toxoplasma encephalitis; (3) Willing to sign the informed consent.
Exclusion criteria
Exclusion criteria: Patients will be excluded from our study if they have the following: (1) Allergic or intolerant to therapeutic medications; (2) Hemoglobin (Hb) 2 UNL, serum creatinine (Scr) >1.5 UNL, aspartate aminotransferase (AST) /alanine aminotransferase (ALT) /alkaline phosphatase (ALP) >5 UNL, total bilirubin (TB) >2 UNL, serum creatine phosphokinase (CK) >2 UNL; (3) Unstable severe concomitant diseases, opportunistic infections other than toxoplasmic encephalitis, or mental illnesses that may affect efficacy assessment or compliance; (4) Pregnant or breastfeeding women; (5) Intravenous recreational drug use; (6) Non-Chinese nationality.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical response rate;all-cause mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical response rate;all-cause mortality;adverse events; | — |
Countries
China
Contacts
Public ContactYao Kaichen
Chongqing Public Health Medical Center
Outcome results
None listed